The clinical value of 123I-metaiodobenzylguanidine myocardial imaging in the diagnosis of dementia with Lewy bodies / 生物医学工程学杂志
Journal of Biomedical Engineering
;
(6): 595-601, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-981581
ABSTRACT
Metaiodobenzylguanidine (MIBG) is an analog of norepinephrine that accumulates in sympathetic nerve endings soon after intravenous administration. The degree of accumulation reflects the uptake, storage and release of transmitters by noradrenergic neurons. Myocardial imaging with 123I labeled MIBG ( 123I-MIBG) can be used to estimate the extent of local myocardial sympathetic nerve damage, which has been widely used in the diagnosis and treatment of various heart diseases. In recent years, numerous studies have been carried out on the application of 123I-MIBG in the diagnosis of degenerative diseases of the nervous system (such as Parkinson's disease and dementia of Lewy body), and have made some achievements. The purpose of this review is to summarize the current clinical application of 123I-MIBG myocardial imaging in the diagnosis of dementia with Lewy bodies, the problems in imaging technology and the possible research directions in the future, so as to provide valuable reference information for clinicians to reasonably and accurately apply this technology in the early diagnosis and discrimination of dementia.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Cuerpos de Lewy
/
3-Yodobencilguanidina
/
Enfermedad por Cuerpos de Lewy
/
Radioisótopos de Yodo
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Biomedical Engineering
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS